Journal of Dermatology最新文献

{"title":"Comparison of efficacy between anti-PD-1 antibody monotherapy and nivolumab plus ipilimumab therapy as first-line immunotherapy for advanced mucosal melanoma in Japanese patients: A single-center, retrospective cohort study","authors":"Ken Horisaki,&nbsp;Shusuke Yoshikawa,&nbsp;Wataru Omata,&nbsp;Arata Tsutsumida,&nbsp;Yoshio Kiyohara","doi":"10.1111/1346-8138.17445","DOIUrl":"10.1111/1346-8138.17445","url":null,"abstract":"<p>Mucosal malignant melanoma (MMM) is a rare subtype of malignant melanoma with a more aggressive biological behavior than cutaneous melanoma (CM). Owing to its rarity, it is necessary to accumulate information on treatments, especially in Asians, in whom MMM occurs more frequently than in Caucasians. In this study, we investigated the efficacy and adverse events (AEs) of nivolumab plus ipilimumab therapy (NIVO+IPI) versus immune checkpoint inhibitor (ICI) monotherapy (PD-1) in Japanese patients with MMM. We reviewed patients with advanced or recurrent MMM who received ICIs as first-line systematic therapy between February 2012 and February 2024 at the Shizuoka Cancer Center. We enrolled a total of 57 patients: 10 (17.5%) were treated with NIVO+IPI, and 47 (82.5%) were treated with PD-1 as first-line systemic therapy. Objective response rates (ORR) did not differ significantly between the NIVO+IPI and PD-1 groups (40.0% vs 27.7%; <i>p</i> = 0.176). There was also no statistically significant difference in progression-free survival (PFS) (median PFS time: 4.3 months vs 9.9 months, log-rank test, <i>p</i> = 0.578) or overall survival (OS) (median OS time: 33.1 months vs. 22.8 months, log-rank test, <i>p</i> = 0.697) between the two groups. However, regarding AEs, grade ≥3 AEs leading to discontinuation of first-line treatment occurred in 80% of patients in the NIVO+IPI group and in 22.6% of patients in the PD-1 group (<i>p</i> = 0.002). No difference was found in the efficacy of NIVO+IPI therapy and anti-PD-1 antibody monotherapy as the first-line treatment for MMM in Japanese patients, but an increase in AEs was observed with combination therapy. This study suggests that patients with MMM may receive less benefit from NIVO+IPI than from PD-1.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"51 11","pages":"1425-1433"},"PeriodicalIF":2.9,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17445","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142267160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perspectives of Japanese patients on psoriatic disease burden: Results from “Psoriasis and Beyond,” the Global Psoriatic Disease Survey","authors":"Masanori Okuse,&nbsp;Masayuki Soekawa,&nbsp;Asako Itakura,&nbsp;Taisuke Kawamura,&nbsp;Sicily Mburu,&nbsp;Susan Frade,&nbsp;Yukari Okubo","doi":"10.1111/1346-8138.17424","DOIUrl":"10.1111/1346-8138.17424","url":null,"abstract":"<p>Psoriatic disease (PsD) is a chronic disease affecting skin (psoriasis) and joints (psoriatic arthritis, PsA) that has a significant impact on patients' quality of life (QOL). We report findings from the Japanese subgroup of patients included in Psoriasis and Beyond: The Global Psoriatic Disease Survey, a cross-sectional, quantitative online survey of patients with self-reported, healthcare professional (HCP)-diagnosed, moderate-to-severe plaque psoriasis, with or without PsA. Eligible patients who were recruited online completed a 25-min internet-based survey in Japanese. We assessed patients' understanding of the systemic nature of PsD, disease burden, perception towards their HCPs, treatment expectations, and satisfaction with care. Of the 148 patients, 74% were females. In total, 65% of patients were aware of the systemic nature of their disease. A minority of patients (27%) were aware that PsA was related to their psoriasis, and 30% and 42% of patients were unaware of any manifestations and comorbidities, respectively, related to PsD. Overall, 21% of patients reported that their disease has a “very large” to “extremely large” impact on their QOL (assessed by Dermatology Life Quality Index score), while the majority (61%) reported a “small” effect or “no effect” at all on QOL. Patients experienced stigma and discrimination and had a negative impact on relationships due to PsD. More patients with psoriasis and concomitant PsA (66%) were satisfied with their current treatment than those with psoriasis alone (46%). Overall, 41% of patients were not involved in deciding their treatment goals. These results suggest that Japanese patients may not be fully aware of the systemic nature of PsD, its manifestations and comorbidities. While these patients were somewhat satisfied with their current treatment, they were only occasionally consulted in deciding treatment goals. Policy measures are required to address the stigma and discrimination experienced by patients. Increased patient participation in their care supports shared decision-making and enhanced treatment outcomes.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"51 10","pages":"1298-1309"},"PeriodicalIF":2.9,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17424","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142176726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Erythema nodosum in northern Finland between 1996 and 2019: A register-based study”","authors":"","doi":"10.1111/1346-8138.17447","DOIUrl":"10.1111/1346-8138.17447","url":null,"abstract":"<p>Lantto R, Jokelainen J, Huilaja L, Sinikumpu S-P. Erythema nodosum in northern Finland between 1996 and 2019: A register-based study. <i>J Dermatol</i>. 2024; 51: 1017–1021. https://doi.org/10.1111/1346-8138.17264</p><p>The first and last names of the authors were swapped and they have been corrected in the online article.</p><p>We apologize for this error.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"51 10","pages":"1374"},"PeriodicalIF":2.9,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17447","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142142263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of clinical features in early-onset severe systemic sclerosis: An analysis from a multicenter prospective observational Japanese cohort","authors":"Saori Uesugi-Uchida,&nbsp;Manabu Fujimoto,&nbsp;Yoshihide Asano,&nbsp;Hirahito Endo,&nbsp;Daisuke Goto,&nbsp;Masatoshi Jinnin,&nbsp;Yasushi Kawaguchi,&nbsp;Sumiaki Tanaka,&nbsp;Takahiro Tokunaga,&nbsp;Katsunari Makino,&nbsp;Takashi Matsushita,&nbsp;Sei-Ichiro Motegi,&nbsp;Ayumi Yoshizaki,&nbsp;Shinichi Sato,&nbsp;Minoru Hasegawa","doi":"10.1111/1346-8138.17403","DOIUrl":"10.1111/1346-8138.17403","url":null,"abstract":"<p>As the clinical course of systemic sclerosis (SSc) varies widely, prognostic indicators have been sought to predict the outcomes of individual patients. Racial differences in SSc render it necessary to validate prognostic indicators in different patient cohorts. In this study, we aimed to assess clinical and laboratory parameters in Japanese patients with early-stage SSc with diffuse cutaneous involvement and/or interstitial lung disease, and identify predictive factors for disease progression. We performed multivariate analyses of baseline clinical information to estimate symptoms 4 years later in Japanese patients with diffuse cutaneous SSc and/or SSc with interstitial lung disease. Patients were enrolled in the study within 5 years of disease onset at 10 Japanese SSc centers. Over 12 years, 115 patients followed up for 4 years were included in this study. The modified Rodnan skin score (mRSS) at 4 years correlated with the baseline mRSS and finger-to-palm distance, defined as the average length from the distal tip of the fourth finger to the distal palmar crease. The percentage predicted vital capacity (%VC) in year 4 positively and negatively correlated with initial %VC and the presence of anti-topoisomerase I antibodies, respectively. The Health Assessment Questionnaire Disability Index (HAQ-DI) at 4 years was positively and negatively associated with baseline HAQ-DI and %VC, respectively. The occurrence of digital ulcers within 4 years was associated with the initial presence of digital ulcers, finger-to-palm distance, and the presence of digital pitting scars and anti-topoisomerase I antibodies. This study identified several factors that may predict the progression of early-stage SSc in Japanese patients. Finger-to-palm distance may be a useful tool for predicting the progression of skin thickening and the development of digital ulcers in the early stages of severe SSc, but larger, long-term prospective studies are needed to confirm our findings.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"51 10","pages":"1290-1297"},"PeriodicalIF":2.9,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17403","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142134977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diffuse planar xanthomatosis in the setting of monoclonal gammopathy of undetermined significance","authors":"Marisa Lenga,&nbsp;Jennifer Nam Choi","doi":"10.1111/1346-8138.17432","DOIUrl":"10.1111/1346-8138.17432","url":null,"abstract":"<p>A woman in her 60s presented to the clinic for progressively accumulating, asymptomatic, yellow plaques for 6 years. Her medical history included monoclonal gammopathy of undetermined significance (MGUS) of IgG lambda light chain subtype for 6 years and hypercholesteremia. On physical examination, well-defined, thin, yellow plaques were located on the eyelids, upper chest, anterior upper arms, axillae, and antecubital fossae without mucosal lesions (Figure 1). Histopathological examination revealed scattered collections of foamy histiocytes in the superficial and midreticular dermis with mild perivascular lymphohistiocytic infiltrate. Lipid panel findings demonstrated a mildly elevated low-density lipoprotein cholesterol at 122 mg/dL (reference &lt; 100 mg/dL). The patient was diagnosed with diffuse planar xanthomatosis in the setting of MGUS. Because the patient did not require treatment for MGUS at the time, skin-directed treatment options were reviewed with the patient, and she elected to treat the left anterior arm with cryotherapy. She was lost to follow-up.</p><p>Diffuse planar xanthomatosis is characterized by the dispersed accumulation of cholesterol-rich material in the skin and can develop in patients either with familial hyperlipidemia or with normal and slightly elevated lipids without family history.<span>^{1, 2}</span> In normolipidemic patients, there is a described phenomenon of diffuse xanthomas forming in the setting of hematological or lymphoproliferative disorders.<span>¹</span> Xanthomas form in the setting of MGUS (most commonly the IgG kappa subtype) through the creation of monoclonal IgG and low-density lipoprotein complexes and the subsequent phagocytosis of these complexes by macrophages.<span>³</span> This disease presents as asymptomatic, symmetric, yellow to orange plaques most commonly on the eyelids, neck, upper trunk, and flexural folds.<span>⁴</span> Histopathologic examination demonstrates diffuse foamy cells in the dermis with variable numbers of giant cells, lymphocytes, and foamy histiocytes.<span>⁴</span> Xanthomatosis may resolve spontaneously, with the treatment of MGUS, or with intervention like excision, chemabrasion, ablative laser, and cryotherapy.<span>^{3, 4}</span></p><p>This case serves as representative examination findings to improve clinical recognition of diffuse xanthomatosis in the setting of MGUS.</p><p>The authors declare no conflicts of interest for this article.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"51 10","pages":"e327-e328"},"PeriodicalIF":2.9,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17432","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142020062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in skin bacterial flora during the healing process of ulcer caused by self-destruction of lymph nodes due to tuberculous lymphadenitis","authors":"Makoto Kondo,&nbsp;Daiki Goto,&nbsp;Koji Habe,&nbsp;Naohisa Yamazoe,&nbsp;Keiichi Yamanaka","doi":"10.1111/1346-8138.17433","DOIUrl":"10.1111/1346-8138.17433","url":null,"abstract":"<p>An 86-year-old woman with residual left hemiplegia from a prior stroke, residing in a nursing facility, presented with swelling of the right side of her neck. Tuberculous lymphadenitis was diagnosed through polymerase chain reaction analysis and sputum culture, leading to treatment with isoniazid, rifampicin, and ethambutol. After 2 months, an abscess and ulcer formed; analysis of the bacterial flora of the ulcer revealed a <i>Pseudomonas</i> infection. Treatment with a topical iodine-containing ointment eradicated the <i>Pseudomonas</i> and led to increased diversity with the emergence of species from the Eukaryota and Archaea kingdoms. Subsequently, a loss of diversity occurred, ultimately resulting in a dominance of <i>Escherichia-Shigella</i>. We suggest that the bacterial flora of early ulcers may be dominated by multidrug-resistant <i>Pseudomonas</i>. <i>Escherichia-Shigella</i> may emerge during the ulcer healing process. We, therefore, strongly encourage recognition of the fact that individuals with tuberculosis are immunocompromised and emphasize the critical importance of early intervention in such infections.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"51 11","pages":"1492-1495"},"PeriodicalIF":2.9,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17433","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142001635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tapinarof cream for the treatment of plaque psoriasis: Efficacy and safety results from 2 Japanese phase 3 trials","authors":"Atsuyuki Igarashi,&nbsp;Gaku Tsuji,&nbsp;Shuichi Fukasawa,&nbsp;Ryusei Murata,&nbsp;Satoshi Yamane","doi":"10.1111/1346-8138.17423","DOIUrl":"10.1111/1346-8138.17423","url":null,"abstract":"<p>Tapinarof is a non-steroidal, topical, aryl hydrocarbon receptor agonist. We evaluated the efficacy and safety of tapinarof cream (1%) in Japanese patients aged ≥18 years with plaque psoriasis in two phase 3 trials, ZBA4-1 and ZBA4-2. ZBA4-1 (<i>N</i> = 158) consisted of a 12-week, double-blind, vehicle-controlled treatment period (period 1) and a 12-week extension treatment period (period 2). Patients were randomized 2:1 to tapinarof or vehicle in period 1; subsequently, all patients who were enrolled in period 2 received tapinarof. ZBA4-2 (<i>N</i> = 305) was a 52-week, open-label, uncontrolled trial in which all patients received tapinarof. In period 1 of ZBA4-1, the proportion of patients who achieved a Physician Global Assessment (PGA) score of 0 (clear) or 1 (almost clear) with ≥2-grade improvement from baseline at week 12 (PGA treatment success, the primary endpoint) was 20.06% in the tapinarof group and 2.50% in the vehicle group (<i>p</i> = 0.0035). The proportion of patients with ≥75% improvement from baseline in the Psoriasis Area and Severity Index (PASI) score at week 12 (PASI75 response, a key secondary endpoint) was 37.7% in the tapinarof group and 3.8% in the vehicle group (<i>p</i> &lt; 0.0001). In ZBA4-2, PGA treatment success rate was 30.0% at week 12, 51.3% at week 24, and 56.3% at week 52, and PASI75 response rate was 50.4% at week 12, 77.5% at week 24, and 79.9% at week 52, indicating that efficacy responses improved over time and were maintained over 52 weeks. Across the two trials, most adverse events (AEs) were mild or moderate; common AEs included folliculitis and contact dermatitis. In summary, tapinarof cream (1%) was efficacious and generally safe for up to 52 weeks of treatment in Japanese patients with plaque psoriasis.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"51 10","pages":"1269-1278"},"PeriodicalIF":2.9,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17423","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141989816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rosacea in East Asian populations: Clinical manifestations and pathophysiological perspectives for accurate diagnosis","authors":"Yoshimasa Nobeyama","doi":"10.1111/1346-8138.17411","DOIUrl":"10.1111/1346-8138.17411","url":null,"abstract":"<p>Rosacea is a chronic inflammatory disorder primarily affecting the facial skin, prominently involving the cheeks, nose, chin, forehead, and periorbital area. Cutaneous manifestations encompass persistent facial erythema, phymas, papules, pustules, telangiectasia, and flushing. The pathogenesis of rosacea is associated with various exacerbating or triggering factors, including microbial infestation, temperature fluctuations, sunlight exposure, physical exertion, emotional stress, consumption of hot beverages and spicy foods, and exposure to airborne pollen. These environmental factors interact with genetic predispositions in the development of rosacea. The roles of the lipophilic microbiome, ultraviolet radiation, nociceptive responses, and vascular alterations have been proposed as significant factors in the pathogenesis. These insights contribute to understanding the anatomical specificity of facial involvement and the progressive nature of rosacea. East Asian skin, predominantly classified as Fitzpatrick skin phototypes III to IV, is characterized by relatively diminished skin barrier function and increased sensitivity to irritants. Airborne pollen exposure may particularly act as a trigger in East Asian individuals, possibly mediated through toll-like receptors. The lack of specificity in objective clinical and histopathological findings leads to diagnostic challenges for individuals with colored skin, including East Asians, particularly when erythema is the sole objective manifestation. An alternative diagnostic scheme may thus be necessary. A diagnostic approach emphasizing vascular manifestations and nociceptive symptoms potentially holds promise for individuals with darker skin tones. More research focusing on potential variations in skin physiology across different racial groups is essential to establish more effective diagnostic schemes applicable to both dark and light skin colors.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"51 9","pages":"1143-1156"},"PeriodicalIF":2.9,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141914976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of new antifungal medications on onychomycosis prescriptions and costs in Japan: A nationwide claims database study","authors":"Hideaki Miyachi,&nbsp;Daisuke Sato,&nbsp;Kentaro Sakamaki,&nbsp;Yaei Togawa,&nbsp;Kensuke Yoshimura","doi":"10.1111/1346-8138.17393","DOIUrl":"10.1111/1346-8138.17393","url":null,"abstract":"<p>Onychomycosis, a fungal nail infection, is a common dermatological condition in Japan, with a prevalence of approximately 5%–10%. Despite the introduction of new antifungal medications and updated treatment guidelines published in 2019, data on real-world prescription trends and the associated medical costs are limited. This study aimed to investigate the prescription patterns and medical costs of topical and oral antifungal medications for onychomycosis in Japan from fiscal years 2014 to 2021 using the National Database of Health Insurance Claims and Specific Health Checkups of Japan Open Data. We analyzed the annual prescription volumes and medical costs of four antifungal medications: efinaconazole, luliconazole, fosravuconazole, and terbinafine. The prescription volume of efinaconazole, a topical medication launched in 2014, rapidly increased and dominated the market share. Fosravuconazole, an oral medication introduced in 2018, showed an increasing trend, coinciding with a decline in efinaconazole prescriptions. Terbinafine, a well-established oral medication, experienced a substantial decrease in prescription volume. The sex- and age-adjusted prescription volume per 100 000 population was higher among older adults, particularly for efinaconazole. The total medical costs for onychomycosis treatment more than doubled in fiscal year 2015 compared with that for 2014, mainly driven by efinaconazole prescriptions, and exceeded 30 billion Japanese yen in fiscal years 2019–2021. The costs slightly decreased in fiscal years 2020 and 2021, possibly due to the introduction of fosravuconazole. The predominance of topical prescriptions, especially in older adults, raises concerns regarding adherence to the Japanese guidelines that recommend oral antifungals as the first-line treatment for onychomycosis. The substantial increase in medical costs also highlights the economic burden of onychomycosis and the need for cost-effective treatment strategies. This study provides valuable insights into the real-world prescription trends and medical costs of onychomycosis treatment in Japan, suggesting an opportunity to assess potential gaps between guideline recommendations and clinical practice.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"51 9","pages":"1172-1179"},"PeriodicalIF":2.9,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17393","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141904110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to ‘Case of systemic sclerosis overlapping with neuromyelitis optica’","authors":"","doi":"10.1111/1346-8138.17416","DOIUrl":"10.1111/1346-8138.17416","url":null,"abstract":"<p>Odagaki A, Akatsuka T. Case of systemic sclerosis overlapping with neuromyelitis optica. <i>J Dermatol</i>. 2022;49:e40–e41. https://doi.org/10.1111/1346-8138.16216</p><p>In Ayaka Odagaki, Taro Akatsuka, ‘Case of systemic sclerosis overlapping with neuromyelitis optica’ <i>The Journal of Dermatology</i>, Volume 49, Issue 1, Tsutomu Ohtsuka was listed as an author alongside Ayaka Odagaki and Taro Akatsuka. Tsutomu Ohtsuka has since relinquished his claim to copyright in the contents of the Letter and therefore only Ayaka Odagaki and Taro Akatsuka should be listed as authors. Ayaka Odagaki (<span>[email protected]</span>) is listed as the new Corresponding Author of the Letter.</p><p>The online article has been corrected.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"51 9","pages":"1264"},"PeriodicalIF":2.9,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17416","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141877115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}